May 11, 2021- Our off-the-shelf cell therapy technology is licensed by a Biotech startup, Appia Bio, for commercial development. The company launches with $52 million Series A financing. [Appia News][Endpoints News]
August 5, 2021- Appia Bio and Kite announce collaboration to research and develop allogeneic cell therapies for cancer; Appia Bio will receive an upfront payment, an equity investment, and additional milestone payments for a total value of up to $875 million as well as tiered royalties. [Businesswire News]